Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)

Last updated: April 16, 2025
Sponsor: Sierra Eye Associates
Overall Status: Active - Recruiting

Phase

2

Condition

Diabetic Macular Edema

Macular Edema

Diabetic Retinopathy

Treatment

RGX-314 Dose 2

RGX-314 Dose 1

Aflibercept (2.0 mg)

Clinical Study ID

NCT06942520
SEA1979
  • Ages 25-89
  • All Genders

Study Summary

Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Type I or Type II diabetes mellitus with center involving diabetic macular edemawith previous treatment

  • HbA1c ≤12%

  • BCVA in study eye 78 to 25 ETDRS letters (~20/32 to 20/320) at screening

  • Decreased visual acuity attributable primarily due to CI - DME

  • Demonstrate clinical response to aflibercept injection in the study eye

  • Provide written informed consent

Exclusion

Exclusion Criteria:

  • Women of childbearing potential

  • Neovascularization in the study eye from a cause other than DR

  • Evidence in the study eye of optic nerve pallor on clinical examination

  • History of pan retinal photocoagulation in the study eye

  • Any concurrent ocular condition in the study eye other than CI-DME that couldrequire surgical intervention within 6 months or any condition in the study eye thatmay increase the risk to the participant, require either medical or surgicalintervention during the study to prevent or treat vision loss, or interfere with thestudy procedures or assessments

  • Presence of an implant in the study eye at screening (excluding intraocular lens)

  • Any condition in the investigator's opinion that could limit VA improvement in thestudy eye

  • Active or history of glaucoma, steroid response, or ocular hypertension

  • Any prior intravitreal steroid injection in the study eye within 6 months prior toscreening, administration in the study eye of Ozudrex® within 12 months prior toscreening, or administration in the study eye if Iluven® within 36 months prior toscreening

  • Diabetic macular edema diagnosis ≥ 7 years

  • History of chronic renal failure requiring dialysis or kidney transplant

  • Participation in any other gene therapy study or receipt of any investigationalproduct within 30 days prior to enrollment or 5 half-lives of the investigationalproduct, whichever is longer, or any plans to use an investigational product within 6 months following enrollment

Note: Other inclusion/exclusion criteria apply

Study Design

Total Participants: 18
Treatment Group(s): 3
Primary Treatment: RGX-314 Dose 2
Phase: 2
Study Start date:
March 18, 2025
Estimated Completion Date:
December 31, 2027

Study Description

This Phase 2 trial is an open label, randomized, active controlled, dose-ranging trial to allow for preliminary safety and efficacy data on subretinal (SR) delivery of RGX-314 in participants with CI - DME

Connect with a study center

  • Sierra Eye Associates

    Reno, Nevada 89502
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.